|
Feb 27
|
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
|
|
Feb 25
|
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
|
|
Feb 20
|
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
|
|
Feb 18
|
PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement
|
|
Oct 9
|
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 8
|
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
|
|
Jul 30
|
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024
|
|
Jul 29
|
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
|
|
Jul 23
|
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
|
|
Dec 4
|
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
|
|
Jul 19
|
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage
|
|
Apr 26
|
Are Investors Undervaluing Lucid Diagnostics Inc. (NASDAQ:LUCD) By 43%?
|
|
Apr 25
|
PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
|